Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application

Beatrice Campanella, Tommaso Lomonaco, Edoardo Benedetti, Massimo Onor, Riccardo Nieri, Federica Marmorino, Chiara Cremolini and Emilia Bramanti
Additional contact information
Beatrice Campanella: National Research Council of Italy, C.N.R., Institute of Chemistry of Organometallic Compounds—ICCOM, Via G. Moruzzi 1, 56124 Pisa, Italy
Tommaso Lomonaco: Department of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 15, 56124 Pisa, Italy
Edoardo Benedetti: Hematology Unit, Department of Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56127 Pisa, Italy
Massimo Onor: National Research Council of Italy, C.N.R., Institute of Chemistry of Organometallic Compounds—ICCOM, Via G. Moruzzi 1, 56124 Pisa, Italy
Riccardo Nieri: National Research Council of Italy, C.N.R., Institute of Chemistry of Organometallic Compounds—ICCOM, Via G. Moruzzi 1, 56124 Pisa, Italy
Federica Marmorino: Unity of Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Roma 67, 56127 Pisa, Italy
Chiara Cremolini: Unity of Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Via Roma 67, 56127 Pisa, Italy
Emilia Bramanti: National Research Council of Italy, C.N.R., Institute of Chemistry of Organometallic Compounds—ICCOM, Via G. Moruzzi 1, 56124 Pisa, Italy

IJERPH, 2022, vol. 19, issue 10, 1-8

Abstract: Background . Salivary metabolomics is garnering increasing attention in the health field because of easy, minimally invasive saliva sampling. Dihydrouracil (DHU) is a metabolite of pyrimidine metabolism present in urine, plasma, and saliva and of fluoropyrimidines-based chemotherapeutics. Its fast quantification would help in the identification of patients with higher risk of fluoropyrimidine-induced toxicity and inborn errors of pyrimidine metabolism. Few studies consider DHU as the main salivary metabolite, but reports of its concentration levels in saliva are scarce. We propose the direct determination of DHU in saliva by reversed-phase high-performance liquid chromatography (RP-HPLC-UV detector) as a simple, rapid procedure for non-invasive screening. Methods . The method used was validated and applied to 176 saliva samples collected from 21 nominally healthy volunteers and 4 saliva samples from metastatic colorectal cancer patients before and after receiving 5-fluorouracil chemotherapy. Results. DHU levels in all samples analyzed were in the μmol L −1 range or below proving that DHU is not the main metabolite in saliva and confirming the results found in the literature with LC-MS/MS instrumentation. Any increase of DHU due to metabolism dysfunctions can be suggestive of disease and easily monitored in saliva using common, low-cost instrumentation available also for population screening.

Keywords: saliva; dihydrouracil; chemotherapy metabolite; high-performance liquid chromatography (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/10/6033/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/10/6033/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:10:p:6033-:d:816431

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().